SCHEDULE 13G/A: BlackRock Discloses 8.7% Passive Stake in Altimmune, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.7% of Altimmune, Inc.'s common stock as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 6,159,305 shares of Altimmune, Inc. common stock as of December 31, 2024.
• This stake represents 8.7% of Altimmune, Inc.'s total outstanding common stock.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported ownership position.
• BlackRock, Inc. holds sole voting power over 6,062,860 shares and sole dispositive power over 6,159,305 shares.
• The securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing the control of Altimmune, Inc.
• The filing was made by BlackRock, Inc. as a parent holding company, with various subsidiaries, including BlackRock Advisors, LLC and BlackRock Institutional Trust Company, National Association, beneficially owning shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook. It reflects a standard institutional investment.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a major institutional asset manager, BlackRock, in Altimmune, Inc. Such investments are common for large funds seeking diversified exposure to various sectors, including biotechnology, which Altimmune operates in. It does not necessarily imply a strategic move beyond portfolio allocation.

Stakeholder Impact

• Shareholders may view BlackRock's significant stake as a vote of confidence or a signal of long-term institutional interest in Altimmune, Inc.

Key Dates

Keywords

Altimmune Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Equity Stake